First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, earl…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
-37.0% vs SMA 50 · -36.9% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $259.2M $252.1M–$266.8M | — | $0.02 | — | ±4% | Moderate3 |
FY2024 | $290.8M $277.6M–$298.4M | ▲ +12.2% | $0.96 | ▲ +4309.4% | ±4% | Moderate4 |
FY2025 | $296.7M $295.9M–$297.5M | ▲ +2.0% | $0.90 | ▼ -6.4% | ±2% | Moderate3 |
Dividend per payment — last 8 periods
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, earl…

praxair, inc., a fortune 250 company with 2014 sales of $12.3 billion, is the largest industrial gases company in north and south america and one of the largest worldwide. the company produces, sells and distributes atmospheric, process and specialty gases, and high-performance surface coatings. praxair products, services and technologies are making our planet more productive by bringing efficiency and environmental benefits to a wide variety of industries, including aerospace,chemicals,food and beverage, electronics, energy, healthcare, manufacturing, metals and many others. more information about praxair, inc. is available at www.praxair.com.